First Trust Advisors
TEVA icon

First Trust Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

First Trust Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361K Buy
10,657
+1,038
+11% +$34.6K ﹤0.01% 2488
2026
Q1 		$290K Buy
9,619
+539
+6% +$17.3K ﹤0.01% 2474
2025
Q4 		$283K Buy
+9,080
New +$224K ﹤0.01% 2475
2025
Q1 		– Sell
-29,818
Closed -$657K – 2621
2024
Q4 		$657K Sell
29,818
-58,194
-66% -$1.06M ﹤0.01% 2168
2024
Q3 		$1.59M Buy
88,012
+8,632
+11% +$151K ﹤0.01% 1855
2024
Q2 		$1.29M Sell
79,380
-205,193
-72% -$3.16M ﹤0.01% 1867
2024
Q1 		$4.02M Buy
+284,573
New +$3.59M ﹤0.01% 1407
2017
Q3 		– Sell
-612,724
Closed -$20.4M – 2456
2017
Q2 		$20.4M Buy
612,724
+58,414
+11% +$1.81M 0.05% 491
2017
Q1 		$17.8M Buy
554,310
+29,157
+6% +$995K 0.05% 555
2016
Q4 		$19M Buy
525,153
+158,014
+43% +$6.31M 0.06% 480
2016
Q3 		$16.9M Buy
367,139
+31,720
+9% +$1.65M 0.05% 517
2016
Q2 		$16.8M Buy
335,419
+49,019
+17% +$2.61M 0.05% 487
2016
Q1 		$15.3M Buy
286,400
+143,047
+100% +$8.39M 0.05% 487
2015
Q4 		$9.41M Sell
143,353
-12,043
-8% -$744K 0.02% 694
2015
Q3 		$8.77M Sell
155,396
-25,642
-14% -$1.66M 0.03% 723
2015
Q2 		$10.7M Sell
181,038
-7,932
-4% -$489K 0.03% 720
2015
Q1 		$11.8M Buy
188,970
+5,924
+3% +$344K 0.03% 644
2014
Q4 		$10.5M Buy
183,046
+63,919
+54% +$3.56M 0.04% 680
2014
Q3 		$6.4M Sell
119,127
-125
-0.1% -$6.62K 0.03% 900
2014
Q2 		$6.25M Buy
119,252
+21,847
+22% +$1.12M 0.03% 873
2014
Q1 		$5.15M Sell
97,405
-22,918
-19% -$1.06M 0.02% 956
2013
Q4 		$4.82M Sell
120,323
-2,507
-2% -$98.7K 0.02% 968
2013
Q3 		$4.64M Buy
122,830
+14,015
+13% +$547K 0.03% 920
2013
Q2 		$4.27M Buy
+108,815
New +$4.24M 0.03% 862

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

First Trust Advisors's TEVA Position: Q2 2026 in Review

First Trust Advisors increased its Teva Pharmaceuticals (TEVA) stake by 11% in Q2 2026, buying an estimated $34.6K and bringing the position to 10,657 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

First Trust Advisors first reported a position in TEVA in Q2 2013 and has held it in 24 quarters since. The position peaked at $20.4M in Q2 2017. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • First Trust Advisors held 10,657 shares of Teva Pharmaceuticals worth $361K as of Q2 2026.
  • First Trust Advisors bought 1,038 Teva Pharmaceuticals shares in Q2 2026, an estimated $34.6K.
  • Teva Pharmaceuticals made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2488 holding.
  • First Trust Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • First Trust Advisors's Teva Pharmaceuticals position peaked at $20.4M in Q2 2017.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.